I

t was 1978, and a group of prominent biologists had just gotten together to form a new company called Biogen — founded on the back of Nobel Prize-winning discoveries that promised a world in which scientists could clone just about any molecule they could find in nature.

A year later, the company had figured out how to clone interferon, a signaling protein that could treat a form of leukemia. Its scientists went on to develop a hepatitis B vaccine. And, over the intervening years, the Cambridge, Mass.-based Biogen could proudly and consistently claim to be a pillar of American biotech.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy